Literature DB >> 11690653

Delineation of the minimal catalytic domain of human Galbeta1-3GalNAc alpha2,3-sialyltransferase (hST3Gal I).

V Vallejo-Ruiz1, R Haque, A M Mir, T Schwientek, U Mandel, R Cacan, P Delannoy, A Harduin-Lepers.   

Abstract

The CMP-Neu5Ac:Galbeta1-3GalNAc alpha2,3-sialyltransferase (ST3Gal I, EC 2.4.99.4) is a Golgi membrane-bound type II glycoprotein that catalyses the transfer of sialic acid residues to Galbeta1-3GalNAc disaccharide structures found on O-glycans and glycolipids. In order to gain further insight into the structure/function of this sialyltransferase, we studied protein expression, N-glycan processing and enzymatic activity upon transient expression in the COS-7 cell line of various constructs deleted in the N-terminal portion of the protein sequence. The expressed soluble polypeptides were detected within the cell and in the cell culture media using a specific hST3Gal I monoclonal antibody. The soluble forms of the protein consisting of amino acids 26-340 (hST3-Delta25) and 57-340 (hST3-Delta56) were efficiently secreted and active. In contrast, further deletion of the N-terminal region leading to hST3-Delta76 and hST3-Delta105 gave also rise to various polypeptides that were not active within the transfected cells and not secreted in the cell culture media. The kinetic parameters of the active secreted forms were determined and shown to be in close agreement with those of the recombinant enzyme already described (H. Kitagawa, J.C. Paulson, J. Biol. Chem. 269 (1994)). In addition, the present study demonstrates that the recombinant hST3Gal I polypeptides transiently expressed in COS-7 cells are glycosylated with complex and high mannose type glycans on each of the five potential N-glycosylation sites.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11690653     DOI: 10.1016/s0167-4838(01)00257-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  A validated collection of mouse monoclonal antibodies to human glycosyltransferases functioning in mucin-type O-glycosylation.

Authors:  Catharina Steentoft; Zhang Yang; Shengjun Wang; Tongzhong Ju; Malene B Vester-Christensen; María F Festari; Sarah L King; Kelley Moremen; Ida S B Larsen; Christoffer K Goth; Katrine T Schjoldager; Lars Hansen; Eric P Bennett; Ulla Mandel; Yoshiki Narimatsu
Journal:  Glycobiology       Date:  2019-08-20       Impact factor: 4.313

2.  Structural insight into mammalian sialyltransferases.

Authors:  Francesco V Rao; Jamie R Rich; Bojana Rakić; Sai Buddai; Marc F Schwartz; Karl Johnson; Caryn Bowe; Warren W Wakarchuk; Shawn Defrees; Stephen G Withers; Natalie C J Strynadka
Journal:  Nat Struct Mol Biol       Date:  2009-10-11       Impact factor: 15.369

3.  Over-expression of ST3Gal-I promotes mammary tumorigenesis.

Authors:  Gianfranco Picco; Sylvain Julien; Inka Brockhausen; Richard Beatson; Aristotelis Antonopoulos; Stuart Haslam; Ulla Mandel; Anne Dell; Sarah Pinder; Joyce Taylor-Papadimitriou; Joy Burchell
Journal:  Glycobiology       Date:  2010-06-08       Impact factor: 4.313

4.  Expression of Functional Human Sialyltransferases ST3Gal1 and ST6Gal1 in Escherichia coli.

Authors:  Maria Elena Ortiz-Soto; Jürgen Seibel
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

5.  Probing the CMP-Sialic Acid Donor Specificity of Two Human β-d-Galactoside Sialyltransferases (ST3Gal I and ST6Gal I) Selectively Acting on O- and N-Glycosylproteins.

Authors:  Maxence Noel; Pierre-André Gilormini; Virginie Cogez; Nao Yamakawa; Dorothée Vicogne; Cédric Lion; Christophe Biot; Yann Guérardel; Anne Harduin-Lepers
Journal:  Chembiochem       Date:  2017-05-22       Impact factor: 3.164

6.  Engineering of CHO cells for the production of vertebrate recombinant sialyltransferases.

Authors:  Benoit Houeix; Michael T Cairns
Journal:  PeerJ       Date:  2019-02-11       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.